What Is Real-World Evidence (RWE)? A Plain-Language Guide

Quick answer: Real-world evidence (RWE) is the insight we get about how a treatment, drug, or medical device actually works when it is used in everyday care, not in a controlled study. It comes from analyzing real-world data such as de-identified, aggregate records from hospitals, insurance claims, and patient registries. In short, RWE shows how medicines and devices perform in real life, across large groups of people.

If you have ever wondered how experts know whether a drug keeps working years after it is approved, or how it performs in patients who were never part of the original trial, the answer is usually real-world evidence. This guide explains what RWE is, where it comes from, and why it matters, all in plain, simple language.

What is real-world evidence (RWE)?

Real-world evidence is the conclusion or insight drawn from real-world data. Think of it in two steps:

1. First, you collect real-world data (RWD). This is health information created during normal, day-to-day care.
2. Then, you study that data to answer a question. The answer you get is real-world evidence.

A simple way to remember it: real-world data is the raw material, and real-world evidence is the finished insight. One is the ingredients, the other is the meal.

Importantly, this data is used at the population or cohort level, in de-identified and aggregate form. The goal is to understand patterns across large groups of people, not to look at any single, identifiable person.

Real-world data vs real-world evidence: what is the difference?

People often use these two terms as if they mean the same thing, but they do not.

Real-world data (RWD) is the information itself. It is the collection of records generated when people receive care in the real world.

Real-world evidence (RWE) is what you learn after you analyze that data. It is the pattern, trend, or answer that comes out the other side.

Here is an everyday comparison. A weather station collects temperature readings all year. Those readings are the data. When someone studies them and concludes, "summers here are getting warmer," that conclusion is the evidence. RWD and RWE work the same way in healthcare.

Where does real-world data come from?

Real-world data is generated in many places during ordinary care. The most common de-identified, aggregate sources include:

• Electronic health records (EHRs): notes and results from doctor visits, hospitals, and clinics.

• Insurance and billing claims: records of which treatments and services were provided and paid for.

• Patient registries: organized databases that follow groups of people with a specific condition over time.

• Pharmacy records: information about which medicines were dispensed.

• Wearables and health apps: data from devices that track things like heart rate or activity.

When these sources are prepared for research, personal details are removed so the information is de-identified and studied only at the group level. The focus is always on trends across a population, never on any one identifiable individual.

How is RWE different from clinical trials?

Both clinical trials and RWE help us understand whether a treatment is safe and works well. They just do it in different ways.

A clinical trial is a carefully controlled study. Researchers choose who takes part, control the conditions, and often compare a treatment against a placebo. Trials are excellent for proving that a treatment can work under ideal conditions.

Real-world evidence looks at what happens after that, once a treatment is out in the world. It includes the wide mix of people who use a treatment in daily life, including older patients, people with several health conditions at once, and people who may not have qualified for the original trial.

Neither approach is "better." They answer different questions. Clinical trials tell us if something can work. RWE helps tell us how it works in practice, for a much broader range of people, and over a longer period of time.

Why does real-world evidence matter?

RWE has become a big deal in healthcare, and its use is growing fast. Here is why it is so valuable:

• It fills the gaps trials leave behind. Trials are short and involve a limited group. RWE follows treatments for years and across diverse populations.

• It supports faster answers for rare diseases. For very rare conditions, it can be hard or even impossible to run a large trial. RWE can help provide meaningful evidence when a traditional trial is not practical.

• It helps regulators make decisions. Agencies like the U.S. Food and Drug Administration (FDA) now use RWE to support approvals, label updates, and safety reviews. In fact, a study of FDA label expansions found that roughly one in four approvals between 2022 and 2024 included real-world evidence in some form.

• It guides better care. By showing how treatments perform in practice, RWE helps doctors, health systems, and researchers make more informed choices.

Real-world example of RWE in action

To see how this plays out, here is a recent, real development. This shows how seriously regulators now treat real-world evidence.

How long does the RSV vaccine really protect older adults? (2025)

Vaccines for respiratory syncytial virus (RSV) became available for older adults in 2023. Clinical trials showed they worked, but a practical question remained: how well do they hold up season after season in everyday life?

A large real-world study, published in the medical journal JAMA in October 2025, helped answer that. Researchers followed nearly 7,000 adults aged 60 and older who were hospitalized with a respiratory illness at 26 hospitals across 20 U.S. states, over two RSV seasons. By comparing who had been vaccinated and who had not, they found that a single RSV vaccine dose lowered the risk of RSV-related hospitalization by about 58% overall. Protection was strongest in the first year, around 69%, and dropped to roughly 48% in the second year.

Why this matters: a trial showed the vaccine works. Real-world evidence showed how that protection changes over time in ordinary use, which is exactly the kind of insight doctors and health officials need when deciding whether and when people may benefit from another dose.

What makes real-world evidence trustworthy?

Not all real-world data is equally useful. For RWE to be reliable, two things need to be true:

• Relevance: the data has to actually fit the question. It should include the right kind of patients, in enough detail, to answer what you are asking.

• Reliability: the data must be accurate, complete, and collected in a consistent, well-documented way.

Regulators look closely at both. Simply pulling records and calling them "evidence" is not enough. Strong RWE comes from data that is carefully curated, checked for quality, and analyzed with a clear, pre-planned method, all while keeping information de-identified and aggregate.

Common myths about RWE

Myth: "RWE is just guesswork." Not true. Good RWE follows rigorous, pre-planned methods and quality checks, much like a clinical study.

Myth: "RWE means looking at individual patient files." No. Responsible RWE uses de-identified data studied at the population or cohort level. The aim is group-level insight, not information about any identifiable person.

Myth: "RWE replaces clinical trials." No. It complements them. Trials and RWE answer different questions, and they work best together.

Bring clarity to your real-world data

Real-world evidence turns everyday health data into insights that can improve care, guide decisions, and answer questions that traditional studies cannot. The key is starting with high-quality, de-identified data and analyzing it with care.

Better evidence starts with better data. Sidus Insights helps researchers, biopharma organizations, and healthcare stakeholders unlock meaningful insights from high-quality, de-identified real-world data. See how our research-ready datasets can help answer your next clinical or commercial question.

Frequently Asked Questions